Request for Notification From Industry Organizations Interested in Participating in the Selection Process for Nonvoting Industry Representatives; Reopening of Notification Period, 22148 [2014-08968]
Download as PDF
<![CDATA[
ehiers on DSK2VPTVN1PROD with NOTICES
22148
Federal Register / Vol. 79, No. 76 / Monday, April 21, 2014 / Notices
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 13, 2014. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before May 5,
2014. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 6, 2014.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact James Clark
at James.Clark@fda.hhs.gov, or 301–
796–5293 at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 15, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–08970 Filed 4–18–14; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
15:19 Apr 18, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Request for Notification From Industry
Organizations Interested in
Participating in the Selection Process
for Nonvoting Industry
Representatives; Reopening of
Notification Period
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; reopening of comment
period.
The Food and Drug
Administration (FDA) is reopening the
period for industry organizations
interested in participating in the
selection of nonvoting industry
representatives to represent the interests
of the pharmaceutical manufacturing
industry and the pharmacy
compounding industry on the Pharmacy
Compounding Advisory Committee for
the Center for Drug Evaluation and
Research to notify FDA of such interest.
FDA announced a request for
notification of interest in selection of
industry representatives and for
nominations in the Federal Register on
January 13, 2014. This notice requested
industry organizations that were
interested in participation in the
selection process to notify FDA in
writing by February 12, 2014, and stated
that nominations would be accepted for
the two nonvoting vacancies by the
same date. Industry organizations that
did not notify FDA by the deadline of
their interest in participating in the
selection of nonvoting pharmacy
compounding and pharmaceutical
manufacturing industry representatives
have now expressed interest in
participating. Therefore, FDA is
reopening the notification period for an
additional two weeks so that any
interested industry organizations
wanting to participate can notify the
Agency of their interest.
DATES: Any industry organization
interested in participating in the
selection of appropriate nonvoting
members to represent the interests of the
pharmacy compounding industry and
the pharmaceutical manufacturing
industry on the Pharmacy
Compounding Advisory Committee
should send a letter stating the interest
to FDA by May 5, 2014, for the
vacancies announced in the Federal
Register on January 13, 2014 (79 FR
2177).
SUMMARY:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
All letters of interest should
be submitted electronically to PCAC@
fda.hhs.govmailto:, or in writing by mail
to Jayne E. Peterson, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Avenue, Bldg. 31, Rm. 2417,
Silver Spring, MD 20993.
FOR FURTHER INFORMATION CONTACT:
Jayne E. Peterson, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993, 301–796–
9001, FAX: 301–847–8533, email:
PCAC@fda.hhs.gov.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
ADDRESSES:
Dated: April 15, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–08968 Filed 4–18–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Fogarty
International Center Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Fogarty International
Center Advisory Board.
Date: May 13, 2014.
Closed: May 13, 2014 8:00 a.m. to 9:45 a.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\21APN1.SGM
21APN1
]]>Agencies
[Federal Register Volume 79, Number 76 (Monday, April 21, 2014)]
[Notices]
[Page 22148]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-08968]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0001]
Request for Notification From Industry Organizations Interested
in Participating in the Selection Process for Nonvoting Industry
Representatives; Reopening of Notification Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; reopening of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is reopening the period
for industry organizations interested in participating in the selection
of nonvoting industry representatives to represent the interests of the
pharmaceutical manufacturing industry and the pharmacy compounding
industry on the Pharmacy Compounding Advisory Committee for the Center
for Drug Evaluation and Research to notify FDA of such interest. FDA
announced a request for notification of interest in selection of
industry representatives and for nominations in the Federal Register on
January 13, 2014. This notice requested industry organizations that
were interested in participation in the selection process to notify FDA
in writing by February 12, 2014, and stated that nominations would be
accepted for the two nonvoting vacancies by the same date. Industry
organizations that did not notify FDA by the deadline of their interest
in participating in the selection of nonvoting pharmacy compounding and
pharmaceutical manufacturing industry representatives have now
expressed interest in participating. Therefore, FDA is reopening the
notification period for an additional two weeks so that any interested
industry organizations wanting to participate can notify the Agency of
their interest.
DATES: Any industry organization interested in participating in the
selection of appropriate nonvoting members to represent the interests
of the pharmacy compounding industry and the pharmaceutical
manufacturing industry on the Pharmacy Compounding Advisory Committee
should send a letter stating the interest to FDA by May 5, 2014, for
the vacancies announced in the Federal Register on January 13, 2014 (79
FR 2177).
ADDRESSES: All letters of interest should be submitted electronically
to PCAC@fda.hhs.govmailto:, or in writing by mail to Jayne E. Peterson,
Center for Drug Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Avenue, Bldg. 31, Rm. 2417, Silver Spring, MD
20993.
FOR FURTHER INFORMATION CONTACT: Jayne E. Peterson, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993, 301-796-
9001, FAX: 301-847-8533, email: PCAC@fda.hhs.gov.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: April 15, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-08968 Filed 4-18-14; 8:45 am]
BILLING CODE 4160-01-P
